Cited by 598Mitochondrial Function and PathologyAlzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

The DOI matches its Crossref record.

Cytochrome oxidase deficiency in Alzheimer’s disease

Parker, William Davis, Filley, Christopher M., Parks, Janice K.·1990·Neurology

DOI 10.1212/wnl.40.8.1302

Open this paper in CoChat — free account

Abstract

We assayed cytochrome oxidase and other electron transport chain activities in platelet mitochondria isolated from patients with Alzheimer's disease (AD). Five of 6 patients had striking reductions of platelet cytochrome oxidase activity (patient mean, 83.72 +/- 82.99 nmol/min/mg; control mean, 167.14 +/- 36.21 nmol/min/mg; n = 8). Other electron transport chain catalytic activities were not significantly different than control values. AD may be a systemic illness, a primary defect in cytochrome oxidase may be pathogenically important in its production, and the mitochondrial genes encoding cytochrome oxidase subunits may be important in producing the defect.

Integrity signals

Registry

Crossref · 10.1212/wnl.40.8.1302

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Sorted by citations

Items 101–200 of 597

Role of Mitochondria in Neurodegenerative Diseases: Mitochondria as a Therapeutic Target in Alzheimer's Disease
Reddy, P. H. (2009) · CNS Spectrums · doi:10.1017/s1092852900024901 · Cited by 192
Mitochondrial dysfunction in neurodegenerative disorders: Potential therapeutic application of mitochondrial transfer to central nervous system-residing cells
Bustamante-Barrientos, F. A., Luque‐Campos, N., Araya, M. J., Lara-Barba, E., Solminihac, J. D., Pradenas, C., Molina, L., Herrera-Luna, Y., Utreras‐Mendoza, Y., Elizondo-Vega, R. J., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04493-w · Cited by 204
“Non-neural cell types obtained from AD patients, including fibroblasts, peripheral blood cells or platelets, present deregulation of the metabolic enzymes [36, 37].”
Background
Mitochondrial Dysfunction in Alzheimers Disease: Opportunities forDrug Development
Bhatia, S., Rawal, R., Sharma, P., Singh, T., Singh, M., & Singh, V. (2021) · Current Neuropharmacology · doi:10.2174/1570159x19666210517114016 · Cited by 209
“Cytochrome oxidase and pyruvate dehydrogenase enzymes were also found to be deficient in AD patients [92-94].”
Reactive Oxygen Species Mediate Cellular Damage in Alzheimer Disease
Perry, G. L., Castellani, R. J., Hirai, K., & Smith, M. A. (1998) · Journal of Alzheimer s Disease · doi:10.3233/jad-1998-1103 · Cited by 184
Perimenopause and emergence of an Alzheimer’s bioenergetic phenotype in brain and periphery
Mosconi, L., Berti, V., Quinn, C. G., McHugh, P. F., Petrongolo, G., Osorio, R. S., Connaughty, C., Pupi, A., Vallabhajosula, S., Isaacson, R., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0185926 · Cited by 185
Mitochondrial alterations near amyloid plaques in an Alzheimer’s disease mouse model
Xie, H., Guan, J., Borrelli, L. A., Xu, J., Serrano-Pozo, A., & Bacskai, B. J. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1836-13.2013 · Cited by 185
Platelet mitochondrial function: from regulation of thrombosis to biomarker of disease.
Zharikov, S. I., & Shiva, S. (2013) · Biochemical Society Transactions · doi:10.1042/bst20120327 · Cited by 182
Role of Mitochondrial Amyloid-β in Alzheimer's Disease
Chen, J. X., & Yan, S. S. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100357 · Cited by 188
Familial Alzheimer's disease: Site of mutation influences clinical phenotype
Lippa, C. F., Swearer, J. M., Kane, K., Nochlin, D., Bird, T. D., Ghetti, B. F., Nee, L. E., George‐Hyslop, P. S., Pollen, D. A., & Drachman, D. A. (2000) · Annals of Neurology · doi:10.1002/1531-8249(200009)48:3 · Cited by 67
Protective effects of reduced dynamin-related protein 1 against amyloid beta-induced mitochondrial dysfunction and synaptic damage in Alzheimer’s disease
Mańczak, M., Kandimalla, R. J. L., Fry, D., Sesaki, H., & Reddy, P. H. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw330 · Cited by 180
“Several lines of evidence suggest that increased free radical production, lipid peroxidation, oxidative DNA damage, oxidative protein damage and decreased ATP production, and cytochrome oxidase activity in brains from AD patients compared to brains from age-matched control subjects (17,25,31,23,24).”
Background
Mitochondria in Sporadic Amyotrophic Lateral Sclerosis
Swerdlow, R. H., Parks, J. K., Cassarino, D. S., Trimmer, P. A., Miller, S. W., Maguire, D., Sheehan, J. P., Maguire, R. S., Pattee, G. L., Juel, V. C., et al. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6866 · Cited by 180
Self-citation
Reduced dynamin-related protein 1 protects against phosphorylated Tau-induced mitochondrial dysfunction and synaptic damage in Alzheimer’s disease
Kandimalla, R. J. L., Mańczak, M., Fry, D., Yeguvapalli, S., Sesaki, H., & Reddy, P. H. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw312 · Cited by 182
“Dysfunction of mitochondria has been identified in AD postmortem brains (18-22), AD transgenic mice (10, 11, 15, 23-25), and cell lines that express mutant APP”
Background
Creatine and Its Potential Therapeutic Value for Targeting Cellular Energy Impairment in Neurodegenerative Diseases
Adhihetty, P. J., & Beal, M. F. (2008) · NeuroMolecular Medicine · doi:10.1007/s12017-008-8053-y · Cited by 190
Mitochondrial DNA Oxidative Damage and Repair in Aging and Alzheimer's Disease
Santos, R. X., Correia, S. C., Zhu, X., Smith, M. A., Moreira, P. I., Castellani, R. J., Nunomura, A., & Perry, G. L. (2012) · Antioxidants and Redox Signaling · doi:10.1089/ars.2012.5039 · Cited by 182
Role of mitochondrial homeostasis and dynamics in Alzheimer's disease
Selfridge, J. E., E, L., Lu, J., & Swerdlow, R. H. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.057 · Cited by 175
The mitochondria-targeted antioxidant MitoQ extends lifespan and improves healthspan of a transgenic Caenorhabditis elegans model of Alzheimer disease
Ng, L. F., Gruber, J., Cheah, I. K.-M., Goo, C. K., Cheong, W. F., Shui, G., Sit, K. P., Wenk, M. R., & Halliwell, B. B. (2014) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2014.03.003 · Cited by 173
Defective mitophagy and synaptic degeneration in Alzheimer's disease: Focus on aging, mitochondria and synapse
Morton, H., Kshirsagar, S., Orlov, E., Bunquin, L. E., Sawant, N. A., Boleng, L., George, M., Basu, T., Ramasubramanian, B., Pradeepkiran, J. A., et al. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.07.013 · Cited by 172
Peripheral markers in testing pathophysiological hypotheses and diagnosing Alzheimer's disease
Gasparini, L., Racchi, M., Binetti, G. G., Trabucchi, M., Solerte, S. B., Alkon, D. L., Etcheberrigaray, R., Gibson, G. E., Blass, J. P., Paoletti, R., et al. (1998) · The FASEB Journal · doi:10.1096/fasebj.12.1.17 · Cited by 177
Amyloid-β-Induced Mitochondrial Dysfunction
Chen, J. X., & Yan, S. D. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-12208 · Cited by 168
Mitochondria, OxPhos, and neurodegeneration: cells are not just running out of gas
Área-Gómez, E., Guardia‐Laguarta, C., Schon, E. A., & Przedborski, S. (2019) · Journal of Clinical Investigation · doi:10.1172/jci120848 · Cited by 169
The relationship between excitotoxicity and oxidative stress in the central nervous system
Bondy, S. C., & LeBel, C. P. (1993) · Free Radical Biology and Medicine · doi:10.1016/0891-5849(93)90144-j · Cited by 161
Expression patterns of β‐amyloid precursor protein (β‐APP) in neural and nonneural human tissues from alzheimer's disease and control subjects
Arai, H., Lee, V. M. ‐., Messinger, M. L., Greenberg, B., Lowery, D. E., & Trojanowski, J. Q. (1991) · Annals of Neurology · doi:10.1002/ana.410300509 · Cited by 165
Mitochondrial DNA mutations in neurodegeneration
Keogh, M. J., & Chinnery, P. F. (2015) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/j.bbabio.2015.05.015 · Cited by 169
Low-level laser therapy for beta amyloid toxicity in rat hippocampus
Lu, Y., Wang, R., Dong, Y., Tucker, D., Zhao, N., Ahmed, M. E., Zhu, L., Liu, T. C., Cohen, R. M., & Zhang, Q. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.10.003 · Cited by 165
DNA adducts and chronic degenerative disease. Pathogenetic relevance and implications in preventive medicine.
Flora, S. D., Izzotti, A., Randerath, K., Randerath, E., Bartsch, H., Nair, J., Balansky, R. M., van Schooten, F., Degan, P., Fronza, G., et al. (1996) · PubMed · Cited by 162
S-Nitrosylation of DRP1 Does Not Affect Enzymatic Activity and is Not Specific to Alzheimer's Disease
Bossy, B., Petrilli, A. M., Klinglmayr, E., Chen, J., Lütz‐Meindl, U., Knott, A. B., Masliah, E., Schwarzenbacher, R., & Bossy‐Wetzel, E. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100552 · Cited by 165
“For example, Aβ can block mitochondrial protein import and inhibit mitochondrial enzymes such as α-ketoglutarate dehydrogenase and cytochrome c oxidase [9-12].”
Systemic Mitochondrial Dysfunction and the Etiology of Alzheimer's Disease and Down Syndrome Dementia
Coskun, P. E., Wyrembak, J., Derbereva, O., Melkonian, G., Doran, E. W., Lott, I. T., Head, E., Cotman, C. W., & Wallace, D. C. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100351 · Cited by 161
“The brain tissue, platelets, and cell lines from AD patients have been reported to manifest partial defects in mitochondrial oxidative phosphorylation (OXPHOS), specifically respiratory complex IV (cytochrome c oxidase or COX) [24–32].”
A Synergistic Dysfunction of Mitochondrial Fission/Fusion Dynamics and Mitophagy in Alzheimer's Disease
Santos, R. X., Correia, S. C., Wang, X., Perry, G. L., Smith, M. A., Moreira, P. I., & Zhu, X. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100666 · Cited by 162
“: +351 239480012; Fax: +351 239480034; E-mail: venta@ci.uc.pt or pismoreira@gmail.com.”
Method for measuring ATP production in isolated mitochondria: ATP production in brain and liver mitochondria of Fischer-344 rats with age and caloric restriction
Drew, B., & Leeuwenburgh, C. (2003) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00264.2003 · Cited by 161
“From our data and others (7, 8), it appears that electron transport chain complexes are more resilient to reactive oxygen species than previously thought and that any inhibition in ATP production would be a result of a severe impairment to one or more of these complexes (7, 8, 30, 34, 36).”
Background
Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment
Valla, J., Schneider, L., Niedzielko, T., Coon, K. D., Caselli, R., Sabbagh, M. N., Ahern, G. L., Baxter, L., Alexander, G., Walker, D. G., et al. (2006) · Mitochondrion · doi:10.1016/j.mito.2006.10.004 · Cited by 159
“Our Western data, as well as previous literature reports (Parker et al., 1990, 1994a; Parker and Parks, 1995), support the contention that Complex IV is catalytically abnormal in AD while protein levels remain normal; it remains unproven what effect that would have on Complex III, if Complex III…”
BackgroundMethod
Apolipoprotein E and Alzheimer's disease
Troutwine, B., Hamid, L., Lysaker, C. R., Strope, T. A., & Wilkins, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.002 · Cited by 179
The role of mitophagy in the regulation of mitochondrial energetic status in neurons
Han, S., Zhang, M., Jeong, Y. Y., Margolis, D. J., & Cai, Q. (2021) · Autophagy · doi:10.1080/15548627.2021.1907167 · Cited by 151
Combined defects in oxidative phosphorylation and fatty acid β-oxidation in mitochondrial disease
Nsiah-Sefaa, A., & McKenzie, M. (2016) · Bioscience Reports · doi:10.1042/bsr20150295 · Cited by 172
Mitochondrial respiratory chain Complexes I and IV are impaired by β-amyloid via direct interaction and through Complex I-dependent ROS production, respectively.
Bobba, A., Amadoro, G., Valenti, D., Corsetti, V., Lassandro, R., & Atlante, A. (2013) · Mitochondrion (Amsterdam. Print) · doi:10.1016/j.mito.2013.03.008 · Cited by 146
“It is worth noting that the lower activity of Complex IV is not only the most documented impairment of mitochondrial enzyme activity in AD (Castellani et al., 2002; Kish et al., 1992; Maurer et al., 2000; Parker et al., 1990), but it also critically contributes to AD progression (Beal, 2000; Davis et al.”
BackgroundMethod
Cytoplasmic hybrid (cybrid) cell lines as a practical model for mitochondriopathies
Wilkins, H., Carl, S. M., & Swerdlow, R. H. (2014) · Redox Biology · doi:10.1016/j.redox.2014.03.006 · Cited by 152
Mitochondrial trafficking of APP and alpha synuclein: Relevance to mitochondrial dysfunction in Alzheimer's and Parkinson's diseases
Devi, L., & Anandatheerthavarada, H. K. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.07.007 · Cited by 149
Reduced Posterior Cingulate Mitochondrial Activity in Expired Young Adult Carriers of the APOE ε4 Allele, the Major Late-Onset Alzheimer's Susceptibility Gene
Valla, J., Yaari, R., Wolf, A. B., Kusne, Y., Beach, T. G., Roher, A. E., Corneveaux, J. J., Huentelman, M. J., Caselli, R. J., & Reiman, E. M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100129 · Cited by 150
“[9, 17,18]) as well as peripheral cells, prominently including circulating platelets [18–20], indicating a systemic mitochondrial defect.”
Amyloid beta-induced glycogen synthase kinase 3β phosphorylated VDAC1 in Alzheimer's disease: Implications for synaptic dysfunction and neuronal damage
Reddy, P. H. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.06.012 · Cited by 147
State-dependent alterations in mitochondrial complex I activity in platelets: a potential peripheral marker for schizophrenia
Dror, N., Klein, E., Karry, R., Sheinkman, A., Kirsh, Z., Mazor, M., Tzukerman, M., & Ben‐Shachar, D. (2002) · Molecular Psychiatry · doi:10.1038/sj.mp.4001116 · Cited by 146
DNA adducts and chronic degenerative diseases. Pathogenetic relevance and implications in preventive medicine
Flora, S. D., Izzotti, A., Randerath, K., Randerath, E., Bartsch, H., Nair, J., Balansky, R. M., van Schooten, F., Degan, P., Fronza, G., et al. (1996) · Mutation Research/Reviews in Genetic Toxicology · doi:10.1016/s0165-1110(96)00043-7 · Cited by 175
Age‐dependent decline of DNA repair activity for oxidative lesions in rat brain mitochondria
Chen, D., Cao, G., Hastings, T. G., Feng, Y., Pei, W., O'Horo, C., & Chen, J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00916.x · Cited by 139
Mitochondria as a target for neuroprotection: role of methylene blue and photobiomodulation
Yang, L., Youngblood, H. A., Wu, C., & Zhang, Q. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00197-z · Cited by 147
Metabolic Impairment Induces Oxidative Stress, Compromises Inflammatory Responses, and Inactivates a Key Mitochondrial Enzyme in Microglia
Park, L. C. H., Zhang, H., Sheu, K. R., Calingasan, N. Y., Kristal, B. S., LINDSAY, J. G., & Gibson, G. E. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0721948.x · Cited by 139
Oxidative Stress Mediated Mitochondrial and Vascular Lesions as Markers in the Pathogenesis of Alzheimer Disease
Aliev, G., Priyadarshini, M., Reddy, V., Grieg, N. H., Kaminsky, Y., Cacabelos, R., Ashraf, G., Jabir, N. R., Kamal, M. A., Nikolenko, V. N., et al. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666131227161303 · Cited by 138
“The most noted deregulation in mitochondrial enzyme activity is the reduction of COX activity in different brain regions and cellular compartment of AD patients having serious consequences on energy metabolism [79-81].”
Background
Pharmacology of AMPA/Kainate Receptor Ligands and Their Therapeutic Potential in Neurological and Psychiatric Disorders
Lees, G. J. (2000) · Drugs · doi:10.2165/00003495-200059010-00004 · Cited by 138
High frequency of mitochondrial complex I mutations in Parkinson’s disease and aging
Smigrodzki, R. M., Parks, J. K., & Parker, W. D. (2004) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2004.02.020 · Cited by 138
“The latter hypothesis is favored by the specific rather than generalized electron transport chain defects found in PD (complex I deficiency) and Alzheimer’s disease (complex IV deficiency) [50,51].”
BackgroundSelf-citation
Reference charts for respiratory chain activities in human tissues
Chrétien, D., Rustin, P., Bourgeron, T., Rötig, A., Saudubray, J., & Münnich, A. (1994) · Clinica Chimica Acta · doi:10.1016/0009-8981(94)90056-6 · Cited by 139
Mitochondria and Neurodegeneration
Petrozzi, L., Ricci, G., Giglioli, N. J., Siciliano, G., & Mancuso, M. (2007) · Bioscience Reports · doi:10.1007/s10540-007-9038-z · Cited by 139
“…COX activity has been reported by several authors in different brain regions (Bosetti et al. 2002; Kish et al. 1992; Maurer et al. 2000; Mutisya et al. 1994; Simonian and Hyman 1994; Wong-Riley et al. 1997), but also in platelets (Parker et al. 1990b) and fibroblasts of sporadic AD patients.”
Background
Protective Role of Methylene Blue in Alzheimer's Disease via Mitochondria and Cytochrome c Oxidase
Atamna, H., & Kumar, R. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100414 · Cited by 142
“homeostasis, oxidative stress, dimerization of AβPP, and synaptic dysfunction [27–31].”
Mitochondrial Dysfunction in Alzheimer’s Disease: A Biomarker of the Future?
Bell, S., Barnes, K., Marco, M. D., Shaw, P. J., Ferraiuolo, L., Blackburn, D. J., Venneri, A., & Mortiboys, H. (2021) · Biomedicines · doi:10.3390/biomedicines9010063 · Cited by 138
Platelet-mediated transformation of mtDNA-less human cells: analysis of phenotypic variability among clones from normal individuals--and complementation behavior of the tRNALys mutation causing myoclonic epilepsy and ragged red fibers.
Chomyn, A., Lai, S. T., Shakeley, R. M., Bresolin, N., Scarlato, G., & Attardi, G. M. (1994) · PubMed Central · Cited by 135
Two novel kinases phosphorylate tau and the KSP site of heavy neurofilament subunits in high stoichiometric ratios
Roder, H. M., & Ingram, V. M. (1991) · Journal of Neuroscience · doi:10.1523/jneurosci.11-11-03325.1991 · Cited by 133
“Furthermore, a selective deficiency in the respiratory enzyme cytochrome oxidase has been reported in blood platelets of AD patients (Parker et al., 1990).”
Background
Bioenergetic flux, mitochondrial mass and mitochondrial morphology dynamics in AD and MCI cybrid cell lines
Silva, D. F., Selfridge, J. E., Lu, J., E, L., Roy, N., Hutfles, L., Burns, J. M., Michaelis, E. K., Yan, S., Cardoso, S. M., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt247 · Cited by 133
“COX activity in AD or MCI groups is lower than it is in agematched control groups (1,2,41,42).”
Background
Mitochondrial dysfunction and neurodegenerative proteinopathies: mechanisms and prospects for therapeutic intervention
Briston, T., & Hicks, A. R. (2018) · Biochemical Society Transactions · doi:10.1042/bst20180025 · Cited by 131
Mitochondrial autophagy in neural function, neurodegenerative disease, neuron cell death, and aging
Batlevi, Y., & Spada, A. R. L. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.09.009 · Cited by 137
Microglial activation states and their implications for Alzheimer's Disease
Valiukas, Z., Tangalakis, K., Apostolopoulos, V., & Feehan, J. (2025) · The Journal of Prevention of Alzheimer s Disease · doi:10.1016/j.tjpad.2024.100013 · Cited by 167
Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies
Swerdlow, R. H. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21167 · Cited by 128
Mitochondrial toxins in models of neurodegenerative diseases. I: in vivo brain hydroxyl radical production during sytemic MPTP treatment or following microdialysis infusion of methylpyridinium or azide ions
Smith, T. S., & Bennett, J. P. (1997) · Brain Research · doi:10.1016/s0006-8993(97)00429-0 · Cited by 129
Creation and Characterization of Mitochondrial DNA‐Depleted Cell Lines with “Neuronal‐Like” Properties
Miller, S. W., Trimmer, P. A., Parker, W. D., & Davis, R. E. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67051897.x · Cited by 127
Self-citation
Mitochondria as targets for chemotherapy
Gogvadze, V. G., Orrenius, S., & Zhivotovsky, B. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0323-0 · Cited by 127
Shift in brain metabolism in late onset Alzheimer’s disease: Implications for biomarkers and therapeutic interventions
Yao, J., Rettberg, J. R., Klosinski, L. P., Cadenas, E., & Brinton, R. D. (2011) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.10.005 · Cited by 125
“It is well established that complex IV activity is decreased in platelet mitochondria isolated from individuals with AD (Bosetti et al., 2002; Cardoso et al., 2004; Parker et al., 1990, 1994).”
Background
Mitochondria in Alzheimer's disease
Swerdlow, R. H., & Kish, S. J. (2002) · International review of neurobiology · doi:10.1016/s0074-7742(02)53013-0 · Cited by 126
Early-infantile galactosialidosis: Prenatal presentation and postnatal follow-up
Patel, M. S., Callahan, J. W., Zhang, S., Chan, A. K. J., Unger, S., Levin, A. V., Skomorowski, M., Feigenbaum, A. S. J., O’Brien, K., Hellmann, J., et al. (1999) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19990702)85:1 · Cited by 45
Genome instability in Alzheimer disease
Hou, Y., Song, H., Croteau, D. L., Akbari, M., & Bohr, V. A. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.04.005 · Cited by 120
Transcranial Laser Stimulation as Neuroenhancement for Attention Bias Modification in Adults with Elevated Depression Symptoms
Disner, S. G., Beevers, C. G., & Gonzalez-Lima, F. (2016) · Brain stimulation · doi:10.1016/j.brs.2016.05.009 · Cited by 127
Decreased levels of complex III core protein 1 and complex V β chain in brains from patients with Alzheimer’s disease and Down syndrome
Kim, S. H., Vlkolinský, R., Cairns, N. J., & Lübec, G. (2000) · Cellular and Molecular Life Sciences · doi:10.1007/pl00000661 · Cited by 124
Glucose Metabolic Dysfunction in Neurodegenerative Diseases—New Mechanistic Insights and the Potential of Hypoxia as a Prospective Therapy Targeting Metabolic Reprogramming
Han, R., Liang, J., & Zhou, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115887 · Cited by 125
“A similar finding was made in AD brains in 1992 [50,51].”
Result
Cytochrome oxidase in Alzheimer's disease: biochemical, histochemical, and immunohistochemical analyses of the visual and other systems.
Wong-Riley, M., Antuono, P., Ho, K.-C., Egan, R., Hevner, R., Liebl, W., Huang, Z., Rachel, R., & Jones, J. L. (1997) · Vision Research · doi:10.1016/s0042-6989(96)00210-6 · Cited by 127
Relationships Between Mitochondria and Neuroinflammation: Implications for Alzheimer's Disease
Wilkins, H., & Swerdlow, R. H. (2015) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026615666150827095102 · Cited by 124
“However, when compared to aged individuals, AD subjects show further reductions in the activities of cytochrome oxidase (COX), pyruvate dehydrogenase complex, and α-ketoglutarate dehydrogenase complex [1, 4, 6, 8].”
Background
TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration
Gao, J., Wang, L., Yan, T., Perry, G. L., & Wang, X. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.103396 · Cited by 124
Relationships between Mitochondrial Dysfunction and Neurotransmission Failure in Alzheimer’s Disease
Wong, K. Y., Roy, J., Fung, M., Heng, B. C., Zhang, C., & Lim, L. W. (2020) · Aging and Disease · doi:10.14336/ad.2019.1125 · Cited by 122
“The reduced efficacy of COX is the most documented change in AD [20, 59-61], which is associated with (1) a deficiency in its structural complex haem-a [62-64]; (2) transmembrane arrest of translocase of the outer mitochondrial membrane 40 kDa (TOMM40) and translocase of inner membrane subunit 23 (TIM23) protein pore…”
Background
New Insights in the Amyloid-Beta Interaction with Mitochondria
Spuch, C., Ortolano, S., & Fernández-Balbuena, C. N. (2012) · Journal of Aging Research · doi:10.1155/2012/324968 · Cited by 121
“APP and amyloid-beta may block mitochondrial translocation of nuclear-encoded proteins [32], such as components of the electron transport chain [43–45], impairing mitochondrial function.”
Background
Human Diseases with Defects in Oxidative Phosphorylation. 2. F1F0 ATP-Synthase Defects in Alzheimer Disease Revealed by Blue Native Polyacrylamide Gel Electrophoresis
Schägger, H., & Ohm, T. G. (1995) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1995.tb20219.x · Cited by 117
The Creatine Kinase/Creatine Connection to Alzheimer′s Disease: CK Inactivation, APP‐CK Complexes and Focal Creatine Deposits
Bürklen, T. S., Schlattner, U., Homayouni, R., Gough, K. M., Rak, M., Szeghalmi, A. V., & Wallimann, T. (2006) · BioMed Research International · doi:10.1155/jbb/2006/35936 · Cited by 129
Mitochondria-Division Inhibitor 1 Protects Against Amyloid-β induced Mitochondrial Fragmentation and Synaptic Damage in Alzheimer’s Disease
Reddy, P. H., Manczak, M., & Yin, X. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170051 · Cited by 116
The Thiazolidinedione Pioglitazone Alters Mitochondrial Function in Human Neuron-Like Cells
Ghosh, S., Patel, N., Rahn, D. A., McAllister, J., Sadeghi, S., Horwitz, G., Berry, D., Wang, K. X., & Swerdlow, R. H. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.033845 · Cited by 119
Mitochondrial dysfunction and Alzheimer's disease
Maruszak, A., & Żekanowski, C. (2010) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2010.07.004 · Cited by 124
The Neurodegenerative Mitochondriopathies
Swerdlow, R. H. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1095 · Cited by 115
“The AD COX Vmax activity reduction was first shown in platelets in 1990 and brain in 1992 [67,68].”
Is the Western diet adequate in copper?
Klevay, L. M. (2011) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2011.08.146 · Cited by 113
Increased mitochondrial complex I activity in platelets of schizophrenic patients
Ben‐Shachar, D., Zuk, R., Gazawi, H., Reshef, A., Sheinkman, A., & Klein, E. (1999) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145799001649 · Cited by 113
“…cytochrome c oxidase and complex I in brains and platelets of patients with Alzheimer’s and Parkinson’s disease, respectively (Mutisya et al., 1994 ; Parker et al., 1990 ; Schapira et al., 1990), and a significant decline in the activities of all electron transporting enzymes in ageing have been…”
Background
Persistent mitochondrial damage by nitric oxide and its derivatives: neuropathological implications
Bolaños, J. P. (2010) · Frontiers in Neuroenergetics · doi:10.3389/neuro.14.001.2010 · Cited by 110
“…factor for the neuronal death accompanying neurodegenerative disorders, such as Alzheimer’s and Parkinson’s diseases (Ebadi and Sharma, 2003; Atamna and Frey, 2007; Fukui and Moraes, 2008), in which CcO (Parker et al., 1990) and glutathione deﬁ ciency (Perry et al., 1982), are hallmarks.”
Mitochondrial Metabolism Power SIRT2-Dependent Deficient Traffic Causing Alzheimer’s-Disease Related Pathology
Silva, D. F., Esteves, A. R., Oliveira, C. R., & Cardoso, S. M. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9951-x · Cited by 110
Mitochondrial ND5 mutations in idiopathic Parkinson’s disease
Parker, W. D., & Parks, J. K. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.11.093 · Cited by 108
Self-citation
Mitochondria, Cybrids, Aging, and Alzheimer's Disease
Swerdlow, R. H., Koppel, S., Weidling, I., Hayley, C., Ji, Y., & Wilkins, H. M. (2017) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2016.12.017 · Cited by 106
Alzheimer’s Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines
Zádori, D., Veres, G., Szalárdy, L., Klivènyi, P., & Vécsei, L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170929 · Cited by 108
Mitochondrial activity and oxidative stress markers in peripheral blood mononuclear cells of patients with bipolar disorder, schizophrenia, and healthy subjects
Gubert, C., Stertz, L., Pfaffenseller, B., Panizzutti, B., Rezin, G. T., Massuda, R., STRECK, E. L., Gama, C. S., Kapczinski, F. P., & Kunz, M. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.06.018 · Cited by 108
Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease
Honea, R. A., Swerdlow, R. H., Vidoni, E. D., Goodwin, J., & Burns, J. M. (2010) · Neurology · doi:10.1212/wnl.0b013e3181c918cb · Cited by 106
Cause or casualty: The role of mitochondrial DNA in aging and age-associated disease
Chocrón, E. S., Munkácsy, E., & Pickering, A. M. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.09.035 · Cited by 117
Mitochondrial respiration as a target for neuroprotection and cognitive enhancement
Gonzalez-Lima, F., Barksdale, B. R., & Rojas, J. C. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.11.010 · Cited by 105
Long-term electromagnetic field treatment enhances brain mitochondrial function of both Alzheimer's transgenic mice and normal mice: a mechanism for electromagnetic field-induced cognitive benefit?
Dragicevic, N., Bradshaw, P. C., Mamcarz, M. B., Lin, X., Wang, L., Cao, C., & Arendash, G. W. (2011) · Neuroscience · doi:10.1016/j.neuroscience.2011.04.012 · Cited by 104
Therapeutic potential of N-acetylcysteine in age-related mitochondrial neurodegenerative diseases
Banaclocha, M. M. (2001) · Medical Hypotheses · doi:10.1054/mehy.2000.1194 · Cited by 104
Mitochondria-Derived Damage-Associated Molecular Patterns in Neurodegeneration
Wilkins, H. M., Weidling, I. W., Ji, Y., & Swerdlow, R. H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00508 · Cited by 102
Current progress of mitochondrial transplantation that promotes neuronal regeneration
Chang, C.-Y., Liang, M.-Z., & Chen, L. (2019) · Translational Neurodegeneration · doi:10.1186/s40035-019-0158-8 · Cited by 102
The Expression of Several Mitochondrial and Nuclear Genes Encoding the Subunits of Electron Transport Chain Enzyme Complexes, Cytochrome c Oxidase, and NADH Dehydrogenase, in Different Brain Regions in Alzheimer's Disease
Aksenov, M. Y., Tucker, H. M., Nair, P., Aksenova, M. V., Butterfield, D. A., Estus, S., & Markesbery, W. R. (1999) · Neurochemical Research · doi:10.1023/a:1020783614031 · Cited by 102
Mitochondria in Alzheimer's disease and their potential role in Alzheimer's proteostasis
Weidling, I. W., & Swerdlow, R. H. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113321 · Cited by 104
Does the mitochondrial genome play a role in the etiology of Alzheimer’s disease?
Elson, J., Herrnstadt, C., Preston, G., Thal, L., Morris, C., Edwardson, J., Beal, M. F., Turnbull, D., & Howell, N. (2006) · Human Genetics · doi:10.1007/s00439-005-0123-8 · Cited by 116
“Parker et al. (1990) reported that platelet fractions from AD patients had lower levels of cytochrome oxidase activity (COX), complex IV of the mitochondrial electron transfer chain, than did those from aged-matched controls.”
Background
Genetic determinants at the interface of cancer and neurodegenerative disease
Morris, L. G. T., Veeriah, S., & Chan, T. A.-T. (2010) · Oncogene · doi:10.1038/onc.2010.127 · Cited by 97
Cyclosporin A Increases Resting Mitochondrial Membrane Potential in SY5Y Cells and Reverses the Depressed Mitochondrial Membrane Potential of Alzheimer's Disease Cybrids
Cassarino, D. S., Swerdlow, R. H., Parks, J. K., Parker, W. D., & Bennett, J. P. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.8866 · Cited by 98
Self-citation
Twins and twinning
Hall, J. G. (1996) · American Journal of Medical Genetics · doi:10.1002/(sici)1096-8628(19960122)61:3 · Cited by 103
Impact of COVID-19 on Mitochondrial-Based Immunity in Aging and Age-Related Diseases
Ganji, R., & Reddy, P. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.614650 · Cited by 96
“Moreover, levels of circulating mtDNA were found to steadily increase in individuals after 50 years of age (Pinti et al., 2014).”
Background

Authors: Parker, W. D., Filley, C. M., & Parks, J. K.
Affiliations: University of Colorado Denver (US)
ORCID: Filley, Christopher M.
Venue: Neurology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1990-08
Volume: 40
Issue: 8
Pages: 1302-1302
ISSN: 0028-3878 (ISSN-L)
1526-632X
DOI: 10.1212/wnl.40.8.1302
OpenAlex: W1988731658
Cited by: 598
References: 0
Citations by year: 2026: 19 · 2025: 10 · 2024: 12 · 2023: 20 · 2022: 9 · 2021: 22 · 2020: 25 · 2019: 19 · 2018: 18 · 2017: 18 · 2016: 28 · 2015: 10 · 2014: 10 · 2013: 21 · 2012: 15
FWCI: 7.27
Type: journal article
Language: en
Open access: closed
Locations: Neurology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (7r01ns025382-06)
National Institute of Neurological Disorders and Stroke (NS25382)
National Center for Research Resources (RR-69)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Keywords: cytochrome oxidase deficiency, Alzheimer's disease, platelet mitochondria, electron transport chain, mitochondrial dysfunction, systemic disease
MeSH terms: Aged, Alzheimer Disease, Blood Platelets, Electron Transport Complex IV, Electron Transport, Female, Humans, Kinetics, Male, Mitochondria, Reference Values, Cytochrome-c Oxidase Deficiency

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Cytochrome oxidase deficiency in Alzheimer’s disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cited by

Related

Metadata

Record

About these checks